The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.

@article{Belani2010TheRO,
  title={The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.},
  author={Chandra Prakash Belani},
  journal={Cancer investigation},
  year={2010},
  volume={28 4},
  pages={413-23}
}
Reversible epidermal growth factor receptor tyrosine kinase inhibitors are often used for the treatment of non-small cell lung cancer following failure of cytotoxic chemotherapy. While these agents are active in a subset of patients, most develop resistance and progress within the course of 1 year. In nearly half of the cases, acquired resistance is caused by a secondary epidermal growth factor receptor T790M mutation. Irreversible epidermal growth factor receptor tyrosine kinase inhibitors are… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

The design of covalent allosteric drugs.

Annual review of pharmacology and toxicology • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 75 references

Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC (abstract no. 8027)

P. A. Jänne, J. H. Schellens, +9 authors D. R. Camidge
J Clin Oncol 2008, • 2008
View 10 Excerpts
Highly Influenced

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Proceedings of the National Academy of Sciences of the United States of America • 2005
View 4 Excerpts
Highly Influenced

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2007
View 9 Excerpts
Highly Influenced

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2009
View 1 Excerpt

BIBW 2992, a reversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaive patients with adenocarcinoma of the lung and activating EGFR mutations

C. H. Yang, J. Y. Shih, +7 authors V. A. Miller
Paper presented at the 13th World Conference on Lung • 2009
View 2 Excerpts

Similar Papers

Loading similar papers…